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Abstract Metabolic syndrome is associated with increased
propensity for diabetes and cardiovascular disease. Low-
grade inflammation is characteristic of metabolic syndrome.
C-reactive protein, the best characterized biomarker of
inflammation, is also an independent predictor of future
cardiovascular events. This review outlines the role of high-
sensitivity C-reactive protein in contributing to increased
cardiovascular risk in metabolic syndrome by inducing
endothelial cell dysfunction and activating monocytes.
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Introduction
Metabolic syndrome (MetS) comprises a cluster of abnormal-
ities, with insulin resistance and adiposity as central features
[1–3]. Five diagnostic criteria for MetS have been identified
by the National Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III), and the presence of
any of these three features—central obesity, dyslipidemia
(high triglycerides, low high-density lipoprotein [HDL]
cholesterol), hypertension, and impaired fasting glucose—is
considered sufficient to diagnose the syndrome [4]. About
24% of US adults have MetS, and the prevalence increases
with age (44% at age 60 years) [5].
Metabolic Syndrome and Cardiovascular Disease
Individuals with MetS have an increased burden of
cardiovascular disease (CVD) [6–8]. In the Kuopio Ische-
mic Heart Disease study, Lakka et al. [6] convincingly
showed that men with MetS, even in the absence of
baseline coronary artery disease (CAD) or diabetes, had a
significantly increased mortality from CAD. In the Botnia
study, MetS was defined as the presence of at least two of
the following risk factors: obesity, hypertension, dyslipide-
mia, or microalbuminuria. Cardiovascular mortality was
assessed in 3,606 individuals, with a median follow-up of
6.9 years. In women and men, respectively, MetS was seen
in 10% and 15% of participants with normal glucose
tolerance, 42% and 64% of those with impaired fasting
glucose/impaired glucose tolerance, and 78% and 84% of
those with type 2 diabetes mellitus. In individuals with
MetS, the risk for coronary heart disease (CHD) and stroke
was increased threefold (P<0.001) and the risk for
cardiovascular mortality was increased sixfold (12.0% vs
2.2%; P<0.001) [6–8]. Using data from the Third National
Health and Nutrition Examination Survey (NHANES III),
Alexander et al. [7] reported that MetS is very common,
with 44% of the US population over 50 years of age
meeting the NCEP-ATP III criteria. Individuals with MetS
without diabetes had higher CHD prevalence (13.9%), and
those with both MetS and diabetes had the highest
prevalence of CHD (19.2%) compared with those with
neither. MetS was a significant univariate predictor of
prevalent CHD. The Hoorn Study examined 615 men and
749 women aged 50 to 75 years without diabetes or a
S. Devaraj: S. Valleggi: I. Jialal (*)
Laboratory for Atherosclerosis and Metabolic Research,
University of California Davis Medical Center,
4635 2nd Avenue, Research 1 Building, Room 3000,
Sacramento, CA 95817, USA
e-mail: ishwarlal.jialal@ucdmc.ucdavis.edu
S. Devaraj: S. Valleggi: D. Siegel:I. Jialal
Veterans Affairs Medical Center,
Mather, CA, USA
Curr Atheroscler Rep (2010) 12:110–118
DOI 10.1007/s11883-010-0098-3history of CVD at baseline and reported that the NCEP-
ATP III definition of MetS was associated with about a
twofold increase in age-adjusted risk of fatal CVD in men
and nonfatal CVD in women [6–8]. The lower but
significant risks were also obtained using the World Health
Organization, American College of Endocrinology, and
European Group on Insulin Resistance definitions of MetS.
Ford [5,] using the modified NCEP-ATP III criteria on the
NHANES cohort, also reported significantly increased
prevalence of MetS in the US population.
Metabolic Syndrome and Diabetes
Besides the effect on cardiovascular morbidity and mortal-
ity, the components of MetS have been associated with
diabetes. Hanson et al. [9] used factor analysis to identify
the components of MetS on 1918 Native Americans of the
Pima tribe. Insulin resistance factor was strongly associated
with diabetes in a 4-year follow-up. Also, the body size and
the lipid factor predicted diabetes whereas the blood
pressure factor did not.
In the West of Scotland Coronary Prevention Study
(WOSCOPS), MetS increased the risk for CHD events and
diabetes [10]. MetS continued to predict CHD events in a
multivariate model incorporating conventional risk factors.
Participants with four or five features of the syndrome had a
3.7-fold increase in risk for CHD and a 24.5-fold increase in
risk for diabetes compared with those with no features of the
syndrome. The Prospective Cardiovascular Münster (PRO-
CAM) study [11] also reported a 2.3-fold increased incidence
of CVD in participants with MetS, and these effects persisted
after adjustment for conventional risk factors.
Overall, MetS confers an increased propensity to both
diabetes and CVD. Although individual components of MetS
independently contribute to increased cardiovascular risk, in
concert they do not explain the increased propensity of
vascular disease in individuals with MetS, and the precise
mechanisms for this increased propensity remain to be
elucidated. Inflammation is pivotal in all phases of athero-
sclerosis, from foam cell formation to culmination in acute
coronary syndromes. It appears that low-grade chronic
inflammationisa central feature ofMetS and could contribute
to increased risks of both CVD and diabetes in MetS.
Inflammation, High-Sensitivity C-Reactive Protein,
and Increased Cardiovascular Risk
Evidence supporting the hypothesis that elevated C-reactive
protein (CRP) levels contribute to increased cardiovascular
risk is now available from at least six major prospective
studies [12]. These are the Physician’s Health Study (PHS)
[13], Women’s Healthy Study (WHS) [14], Atherosclerosis
Risk in Communities (ARIC) study [15], and Air Force/
Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS) [16] in the United States and the
Monitoring Trends and Determinants on Cardiovascular
Diseases/Cooperative Health Research in the Region of
Augsburg (MONICA/KORA Augsburg) [17] and the Age
Gene/Environment Susceptibility (AGES)-Reykjavik [18]
studies in Europe. The largest of the American cohorts is
the WHS, a prospective evaluation of 27,939 initially
healthy American women who underwent high-sensitivity
CRP (hsCRP) evaluation along with a full lipid panel and
Framingham risk assessment and were monitored over a
period of 8.3 years for the occurrence of first-ever
cardiovascular events. Overall, baseline hsCRP levels in
the WHS were a strong predictor of future vascular events;
the relative risks for those with lowest to highest quintiles
of hsCRP at baseline were 1.0, 1.8, 2.3, 3.2, and 4.5 (P<
0.001). After adjustment for age, smoking, diabetes, blood
pressure, and hormone replacement therapy, the risk in the
top quintile of hsCRP was 2.3 (95% CI, 1.6–3.4). A
combined approach, using both a lipid panel and hsCRP,
provided improved prediction of cardiovascular event–free
survival. Most importantly, hsCRP levels remained a highly
significant predictor of risk in the WHS after adjustment for
the Framingham Risk Score. Data on hsCRP from the PHS
and WHS have been corroborated by similar analyses from
other large cohorts from the United States and Europe. In a
case-cohort analysis of 12,819 apparently healthy middle-
aged men and women participating in the ARIC study over
a 6-year follow-up period, the relative risks of incident
CHD for those with baseline hsCRP levels less than 1.0, 1.0
to 3.0, and greater than 3.0 mg/L were 1.0, 1.6, and 2.5,
respectively, after adjusting for age, gender, and ethnicity
[15]. Almost identical data were derived from a prospective
evaluation of 3435 German men participating in the
MONICA/KORA Augsburg Cohort Study, in which 191
incident coronary events occurred during 6.6 years of
follow-up [17]. In this study of men, as in the WHS study
of women, hsCRP levels at baseline were independently
associated with incident coronary events. These effects
remained significant (P < 0.001) after adjustment for
Framingham Risk Score. The Reykjavik Study included
2,459 incident events during an 18-year follow-up period
[18]. Although this prospective study used an hsCRP cut-
point for relative risk of 2.0 rather than 3.0, and thus would
tend to underestimate effects compared with other cohorts,
a highly significant fully adjusted odds ratio of 1.5 was
observed. Within the AFCAPS/TexCAPS analysis of 5,742
apparently healthy individuals enrolled in a randomized
primary prevention trial of lovastatin versus placebo, each
quartile increase in baseline hsCRP was associated with a
21% increase in the risk of a first cardiovascular event
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control for all individual components of the Framingham
Risk Score [16]. Similarly, in an analysis of 1,666
individuals free of CVD enrolled in the Pravastatin
Inflammation/CRP Evaluation (PRINCE) study, hsCRP
levels correlated modestly with 10-year Framingham Risk
Scores yet showed minimal relation to any individual
component of the score itself.
Inflammation, High-Sensitivity C-Reactive Protein,
and Increased Cardiovascular Risk in Metabolic
Syndrome
Numerous studies have now confirmed that CRP levels are
elevated in individuals with MetS [12]. Furthermore, it has
been proposed that hsCRP be added as a clinical criterion
for MetS and for creation of an hsCRP-modified CHD risk
score [12].
With regard to MetS, Yudkin et al. [19], conducted Z-
score analyses in a study 107 nondiabetic individuals and
found a very significant correlation between inflammatory
markers and several features of the MetS. CRP levels were
shown to be strongly associated with insulin resistance
calculated from the homeostatic model assessment, blood
pressure, low HDL, and triglycerides, and also to levels of
the proinflammatory cytokines interleukin-6 (IL-6) and
tumor necrosis factor (TNF). Body mass index and insulin
resistance were the strongest determinants of the inflam-
matory state. There is a linear relationship between the
number of metabolic features and increasing levels of
hsCRP. Furthermore, Festa et al. [20], in the Insulin
Resistance and Atherosclerosis Study (IRAS), showed that
hsCRP was positively correlated with body mass index,
waist circumference, blood pressure, triglycerides, choles-
terol, low-density lipoprotein (LDL) cholesterol, plasma
glucose, and fasting insulin, and that it was inversely
correlated with HDL cholesterol and the insulin sensitivity
index. The strongest associations were observed between
CRP levels, central adiposity, and insulin resistance. The
largest study to date that examined the association between
inflammation and MetS was NHANES III [21]. In a
representative sample of the US population (8570 partic-
ipants > 20 years of age), individuals with MetS, defined
using NCEP-ATP III criteria, were more likely than those
without the syndrome to have elevated levels of markers of
inflammation such as CRP, fibrinogen, and leukocyte count.
Ridker et al. [12, 14] evaluated inter-relationships
between CRP, MetS, and incident cardiovascular events
among 14,719 apparently healthy women who were
followed for an 8-year period for myocardial infarction,
stroke, coronary revascularization, or cardiovascular death;
24% of the cohort had MetS at study entry. At baseline,
median CRP levels for those with zero, one, two, three,
four, or five characteristics of the metabolic syndrome were
0.68, 1.09, 1.93, 3.01, 3.88, and 5.75 mg/L, respectively (P
for trend < 0.0001). Over the 8-year follow-up, cardiovas-
cular event-free survival rates based on CRP levels above
or below 3.0 mg/L were similar to survival rates based on
having three or more characteristics of MetS. At all levels
of severity of MetS, CRP added prognostic information on
subsequent risk. Additive effects for CRP were also
observed for those with four or five characteristics of
MetS. Thus, in this study, those who had hsCRP levels of
less than 3 mg/L without MetS had the best cardiovascular
survival, whereas those who had hsCRP levels greater than
3 mg/L with MetS had the worst cardiovascular survival.
An almost identical additive interaction between
hsCRP, MetS, and subsequent vascular risk was observed
in WOSCOPS, a randomized intervention trial of pravas-
tatin that monitored 6447 middle-aged men over a 5-year
period. In WOSCOPS, hsCRP greater than 3 mg/L at
baseline was highly predictive of incident vascular events
after stratification by the presence or absence of MetS
[22]. Specifically, the observed relative risks of future
coronary events in the low-CRP/MetS-absent, high-CRP/
MetS-absent, low-CRP/MetS-present, and high-CRP/
MetS-present subgroups within WOSCOPS were 1.0
(referent), 1.6, 1.6, and 2.8, respectively (P<0.05).
Smaller but consistent effects were observed in the
Cardiovascular Health Study. Suzuki et al. [23] studied
4,017 men and women ≥ 65 years of age without baseline
congestive heart failure (CHF) or diabetes participating in
the Cardiovascular Health Study, an observational study
with 12.2 years follow-up and 966 cases of incident CHF.
Baseline CRP/MetS or IL-6/MetS were defined as presence
of three of six components, with elevated CRP (≥3 mg/L)
or IL-6 (≥2.21 pg/mL) as a sixth component added to
NCEP-ATP III criteria. MetS and elevated inflammation
markers were independently associated with CHF risk
(hazard ratio = 1.32 [95% CI, 1.16–1.51] for MetS; 1.53
[95% CI, 1.34–1.75] for CRP; and 1.37 [95% CI, 1.19–
1.55] for IL-6). There was a 20% relative excess risk
attributed to the combination of MetS and CRP (95% CI,
−44% to 88%). CRP/MetS and IL-6/MetS definitions
reclassified 18% and 13%, respectively, of participants as
having MetS. Both CRP/MetS and IL-6/MetS increased
risk of CHF by 60% compared with those without MetS. In
this study, MetS and inflammation markers provided
additive information on CHF risk in this elderly cohort.
In a cross-sectional study of 3,873 individuals (weighted
to 156 million) aged ≥ 18 years participating in the
NHANES 1999–2000, participants were classified as
having diabetes, MetS according to modified NCEP-ATP
III criteria, or neither condition by low (<1 mg/L),
intermediate (1–3 mg/L), or high (>3 mg/L) CRP levels.
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gender, smoking, and total cholesterol, compared with
those with neither MetS nor diabetes and low CRP levels,
the odd ratios of CVD were 1.99 (95% CI, 1.10–3.59) for
those with no disease and high CRP levels and 2.67 (95%
CI, 1.30–5.48) for those with MetS and intermediate CRP.
Persons with MetS but high CRP had an OR of 3.33 (95%
CI, 1.80–6.16), similar to those with diabetes and low CRP
(3.21; 95% CI, 1.27–8.09). The likelihood of CVD was
highest in those with diabetes who had intermediate CRP
levels (6.01; 95% CI, 2.54–14.20) and in those with
diabetes and high CRP (7.73; 95% CI, 3.99–14.95).
Pischon et al. [25] showed in the Nurses’ Health Study
and Health Professionals Follow-up Study that whereas
MetS was a strong predictor of CHD in both men and
women, CRP was additive in men only. It should be
emphasized that in this study, a modified definition of MetS
was used because waist circumference, blood pressure, and
glucose were not available at baseline. In a smaller
Japanese study by Takeno et al. [26] of 461 patients with
acute myocardial infarction, CRP levels were additive to
MetS in predicting future major adverse cardiac events.
Furthermore, recent investigation relating increased CRP
levels and MetS in 1,044 older (≥65 years) individuals has
also led to the conclusion that MetS is associated with low-
grade systemic inflammation and that the association is
mainly supported by a strong independent correlation
between waist circumference and high hsCRP levels [27].
Collectively, all these studies support the hypothesis that an
increased CRP level in the setting of MetS confers an
increased risk of future cardiovascular events.
Additionally, a genome-wide association study has been
performed among 6,345 apparently healthy women in
whom 336,108 single nucleotide proteins were evaluated
as potential determinants of plasma CRP concentration
[28]. Overall, seven loci that associate with plasma CRP at
levels achieving genome-wide statistical significance were
found. Two of these loci (GCKR and HNF1A) are
suspected or known to be associated with maturity-onset
diabetes of the young, one is a gene-desert region on
12q23.2, and the remaining four loci are in or near the
leptin receptor protein gene, the apolipoprotein E gene, the
IL-6 receptor protein gene, or the CRP gene itself. The
protein products of six of these seven loci are directly
involved in MetS, insulin resistance, β-cell function,
weight homeostasis, and/or premature atherothrombosis.
Thus, it was concluded that common variations in several
genes involved in metabolic and inflammatory regulation
have significant effects on CRP levels, consistent with the
identification of CRP as a useful biomarker of risk for
incident vascular disease and diabetes.
These findings have sparked increased discussion about
the formal addition of hsCRP to the criteria of MetS. In
addition to the prognostic information that hsCRP evalua-
tion might add to the current definition of MetS, there are
several other practical benefits of hsCRP measurement.
First, hsCRP is strongly associated with components of
MetS that are difficult to measure in routine clinical
practice, such as impaired fibrinolysis and insulin resistance
[19, 20]. Also, the widespread availability of commercial
assays for hsCRP has made its measurement simple and
inexpensive. In addition, as hsCRP does not display diurnal
variation and demonstrates long-term stability comparable
with cholesterol, it can be reliably evaluated with a single
nonfasting measurement [29, 30]. The addition of hsCRP
measurement to our present diagnosis of the MetS may
significantly improve the early detection of risk for future
diabetes and cardiovascular events in individuals [31].
Overall, it appears that in individuals with MetS, an
elevated CRP confers a greater risk for cardiovascular
events by activation of monocytes and induction of
endothelial cell dysfunction [32].
C-Reactive Protein, Endothelial Dysfunction,
and Metabolic Syndrome
Endothelial dysfunction (ED) is now recognized to play a
critical role in the initiation and progression of atheroscle-
rotic vascular disease [33–35]. Furthermore, endothelial
function assessment by brachial flow-mediated dilatation is
a surrogate marker of cardiovascular risk [36, 37] and has
been shown to be decreased in MetS [38–43]. It is well
established that the individual components of Mets are
related to ED. Previous studies have shown that obesity,
low HDL cholesterol, impaired glucose tolerance, hyper-
triglyceridemia, and hypertension are associated with
decreased endothelium-dependent vasodilatation [44, 45].
Insulin resistance is also associated with ED [46, 47].
An impressive amount of data now implicates CRP in
inducingendothelialcellactivationanddysfunctioninvitroas
well as in vivo [48–52]. Several observations demonstrated
that CRP levels correlated inversely with endothelial vaso-
reactivity in vivo [53, 54].The most compelling data
implicating CRP as a determinant of ED were studies
demonstrating that human CRP reduced basal and stimulated
nitric oxide release from arterial and venous endothelial cells
[55, 56]. Our group has explored various mechanistic events
involved in CRP-mediated endothelial nitric oxide synthase
(eNOS) inhibition and documented that increased NADPH
oxidase activation and GTPCH1 downregulation are associ-
ated with CRP-mediated eNOS uncoupling in human airway
epithelial cells in vitro [57•]. In vivo studies have shown that
CRP impairs endothelial vasoreactivity and decreases eNOS
activity [48, 49, 51–54]. Guan et al. [58••]s h o w e dt h a ta
single intravenous injection of adeno-associated virus (AAV)
Curr Atheroscler Rep (2010) 12:110–118 113vector with hsCRP to male rats resulted in efficient and
sustained expression of CRP in the liver and other tissues
and an increase in serum CRP to 15 µg/mL at 2 and
4 months. This was associated with an increase in systolic
and mean arterial blood pressure. The authors went on to
show impaired endothelium-dependent vasoreactivity in the
AAV-hsCRP rats versus the control rats administered AAV-
green fluorescent protein. Previously, we have shown that
CRP inhibits prostacyclin synthase, resulting in decreased
prostacyclin, which is a potent vasodilator [50]. Thus, CRP,
by inducing ED, could put individuals with MetS at further
risk for hypertension and CVD.
Individuals with MetS are in a procoagulant state, as
evidenced by increased circulating plasminogen activator
inhibitor-1 (PAI-1). We have shown that CRP induces PAI-
1 and decreases tissue plasminogen activator in endothelial
cells [59, 60]. CRP appears to induce PAI-1 antigen and
activity via upregulation of nuclear factor-κB (NF-κB) and
Rho kinase activities [61].
Individuals with MetS have increased circulating levels
of cell adhesion molecules (CAMs). In 943 70-old
participants (50% women) of the Prospective Investigation
of the Vasculature in Uppsala Seniors (PIVUS) study,
Ingelsson et al. [62] reported that vascular cell adhesion
molecule-1 (VCAM-1), E-selectin, and CRP demonstrated
the strongest associations with MetS and insulin resis-
tance. Also, in the Women’s Health Study, women with
MetS had significantly higher CRP and soluble intercel-
lular adhesion molecule-1 (ICAM-1) levels that correlated
significantly with increased vascular risk [63]. Further-
more, Kressel et al. [64] showed that individuals with
MetS had significantly higher values of CRP, soluble
ICAM, and soluble VCAM compared with those without
MetS [64]. Rosso et al. [65] demonstrated increased
VCAM in individuals with MetS, and this correlated
significantly with the quantitative insulin-sensitivity check
index (QUICKI). We have previously shown in shear
stress and static conditions that CRP upregulates ICAM,
VCAM, NF-κB, and monocyte-endothelial cell adhesion
in a dose-dependent manner [66].
C-Reactive Protein, Monocyte-Macrophages,
and Metabolic Syndrome
The proinflammatory effects of CRP that have been
documented in monocyte-macrophages include induction
of tissue factor, proinflammatory cytokines, reactive oxygen
species, chemokine receptor CCR2, release of matrix metal-
loproteinase (MMP), CD11b expression, and oxidized LDL
uptake as well as inhibition of cholesterol efflux and
lipopolysaccharide (LPS)-induced IL-10 release [67–73,
74•]. Another important in vivo demonstration made recently
is from our group on the induction of myeloperoxidase
activity in macrophages by CRP administration [75].
Several lines of experimental evidence support the role of
monocyte chemotactic protein-1 (MCP-1) in atherogenesis,
insulin resistance, and adipose tissue-mediated inflammation.
Also, CRP has been reported to induce MCP-1 in endothelial
cells [76] and its receptor CCR2 on monocytes [69].
Furthermore, Esposito et al. [77] have reported that in both
obese and non-obese women, IL-10 levels were significantly
lower in women with MetS. In this regard, we have reported
that CRP inhibits LPS-induced IL-10 release from human
monocyte-derived macrophages [78].
Recently, Bisoendial et al. [79] examined whole-blood
expression for 95 inflammatory markers before and after
infusion of 1.25 mg/kg of recombinant human CRP in five
male volunteers using quantitative real-time polymerase
chain reaction analysis. Relevant transcript levels were
measured at baseline and 4 and 8 h after recombinant
human CRP infusion. CRP caused significant upregulation
of MMP-9, MCP-1, plasminogen activator urokinase,
macrophage inflammatory protein 1 α, and NF-κB mRNAs
in peripheral leukocytes. mRNA upregulation of MMP-9
and MCP-1 was 17- and 11-fold, respectively. The
corresponding increase in plasma protein levels of MMP-
9 (78±32 ng/mL to 109±41 ng/mL; P=0.014) and MCP-1
(312±92 pg/mL to 2,590±898 pg/mL; P=0.007) closely
mirrored mRNA findings. Thus, MetS individuals, who
have persistently high CRP levels, may demonstrate
increased leukocyte activation compared with those with
low CRP levels, and this may contribute to increased
cardiovascular risk in these individuals.
Oxidative stress, mainly superoxide, plays a critical
role in the pathogenesis of MetS parameters [80]. Fortuño
et al. [80] have reported increased mononuclear cell
activation in MetS patients compared with control
subjects. They also demonstrate increased superoxide,
nitrotyrosine, and oxidized LDL in MetS patients com-
pared with controls, although MetS patients studied in
this report were on various medications, including statins
(39%) and oral hyperglycemics (21%). Thus, there is an
emergent need to study monocyte biology in drug-naïve
MetS patients with low and high CRP levels, a subject
that has not yet been explored. Furthermore, CRP has
been shown by numerous investigators, including our
group, to result in increased superoxide production as a
result of enhanced NADPH oxidase activity in endothelial
cells as well as in human peripheral blood monocytes
[55, 57•, 68, 73, 81, 82]. Also, in situ hybridization
revealed the presence of CRP mRNA that co-localized
with p22phox, an essential component of NADPH oxidase
[82]. We also demonstrated in Wistar rats that CRP
stimulates superoxide production in macrophages via
upregulation of NADPH oxidase [68].
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has been shown in patients with acute coronary syndrome and
is associated with ED and predicted cardiovascular events
[83]. Furthermore, patients with MetS exhibit increased
plasma oxidized LDL levels [84]. In addition, we recently
showed that CRP promotes oxidized LDL uptake and
cholesterol ester accumulation in Wistar rats [74•].
Patients with MetS are in a procoagulant state. Tissue
factor is increased in morbidly obese persons with
abnormal glucose tolerance compared with those with
normal glucose tolerance [85]. Diamant et al. [85] also
demonstrated increased tissue factor—containing micro-
particles in type 2 diabetes mellitus that correlated
significantly with features of MetS in this population. In
vivo, several lines of evidence indicate that CRP promotes
procoagulant activity [41]. We have shown that CRP
promotes tissue factor activity in vitro and in vivo in the
rat model and shown that it occurs via activation of reactive
oxygen species and NF-κB[ 68].
MMPs and their tissue inhibitors of metalloproteinase
(TIMP) may play a role in cardiovascular complications
associated with MetS. Studies have shown increased levels
of pro-MMP-9, MMP-8, and TIMP-1 in MetS patients
compared with controls [86]. Furthermore, we have
confirmed in vitro and in vivo that CRP augments MMP-
9 release and activity when injected into Wistar rats [74].
NF-κB is a pivotal transcription factor involved in the
induction of specific proinflammatory genes [87]. Studies
in animal models have demonstrated the importance of
IKKβ in the pathogenesis of insulin resistance in obese and
diabetic rodents. Recently, it has also been shown in
humans that obesity is associated with an increase in NF-
κB binding in the nucleus and a decrease in the inhibitory
κb in the mononuclear cells, with increased mRNA for
TNF [88], IL-6, macrophage inhibitory factor, and MMP-9,
consistent with the proinflammatory state. Recently, we
have shown that CRP induces NF-κB activity in rat
macrophages in vivo [68, 74•]. Also, we have previously
shown that in MetS patients, simvastatin therapy decreased
hsCRP levels and mononuclear NF-κB activity [89].
Conclusions
Emerginglaboratoryand clinical evidencehas showna strong
relationship between CRP and various features of MetS. The
additionofCRPtothepresentdefinitionoftheMetSmayhelp
identify patients at high risk for future diabetes and CVD.
Further investigation is clearly needed not only to clarify the
molecularroleofCRPinthepathogenesisofMetS,butalsoto
shed new light on the role of CRP, specifically in mediating
vascular effects and conferring increased risk of cardiovascu-
lar events in MetS patients with high CRP levels. In this
regard, it should be emphasized that the Justification for the
Use of Statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER) [90••] study showed a clear benefit
of statin therapy in patients with CRP greater than 2 mg/L,
and the published evidence base supports a role for statin
therapy in MetS [91].
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